Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 5
1963 4
1964 3
1965 6
1966 6
1967 5
1968 4
1969 5
1970 1
1971 2
1973 3
1974 2
1975 2
1976 5
1977 4
1978 4
1979 6
1980 6
1981 2
1982 7
1983 9
1984 8
1985 10
1986 18
1987 8
1988 15
1989 12
1990 6
1991 17
1992 16
1993 31
1994 21
1995 25
1996 24
1997 24
1998 17
1999 30
2000 25
2001 26
2002 29
2003 26
2004 29
2005 34
2006 24
2007 35
2008 31
2009 30
2010 40
2011 65
2012 64
2013 42
2014 51
2015 39
2016 37
2017 59
2018 43
2019 55
2020 56
2021 66
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

1,210 results
Results by year
Filters applied: . Clear all
Page 1
Parental-to-embryo switch of chromosome organization in early embryogenesis.
Collombet S, Ranisavljevic N, Nagano T, Varnai C, Shisode T, Leung W, Piolot T, Galupa R, Borensztein M, Servant N, Fraser P, Ancelin K, Heard E. Collombet S, et al. Among authors: nagano t. Nature. 2020 Apr;580(7801):142-146. doi: 10.1038/s41586-020-2125-z. Epub 2020 Mar 25. Nature. 2020. PMID: 32238933
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Hiraoka A, et al. Among authors: nagano t. Cancer Rep (Hoboken). 2021 Jun 11:e1464. doi: 10.1002/cnr2.1464. Online ahead of print. Cancer Rep (Hoboken). 2021. PMID: 34114752 Free article.
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, Nagano T, Morishima E, Matsuda N; J-Land 3S Study Group. Kakihana Y, et al. Among authors: nagano t. Lancet Respir Med. 2020 Sep;8(9):863-872. doi: 10.1016/S2213-2600(20)30037-0. Epub 2020 Mar 31. Lancet Respir Med. 2020. PMID: 32243865 Clinical Trial.
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.
Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T. Okada-Iwabu M, et al. Among authors: nagano t. Nature. 2013 Nov 28;503(7477):493-9. doi: 10.1038/nature12656. Epub 2013 Oct 30. Nature. 2013. PMID: 24172895
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Nanba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nishii N, Fuke S, Yoshikawa M, Nakamura K, Ito H; MUSCAT‐HF Study Investigators †. Ejiri K, et al. Among authors: nagano t. J Am Heart Assoc. 2020 Aug 18;9(16):e015103. doi: 10.1161/JAHA.119.015103. Epub 2020 Aug 1. J Am Heart Assoc. 2020. PMID: 32805185 Free PMC article. Clinical Trial.
Novel cancer therapy targeting microbiome.
Nagano T, Otoshi T, Hazama D, Kiriu T, Umezawa K, Katsurada N, Nishimura Y. Nagano T, et al. Onco Targets Ther. 2019 May 13;12:3619-3624. doi: 10.2147/OTT.S207546. eCollection 2019. Onco Targets Ther. 2019. PMID: 31190864 Free PMC article. Review.
1,210 results